Functionally selective ALPHA2C adrenoreceptor agonists
View Patent ↗In its many embodiments, the present invention provides a novel class of indolines as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
1. A compound or a pharmaceutically acceptable salt thereof of the following structure:
2. A solid pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, adjuvant or vehicle.
3. The pharmaceutical composition of claim 2 , additionally further comprising one or more additional therapeutic agents.
4. The pharmaceutical composition of claim 3 , wherein said additional therapeutic agents are selected from the group consisting of steroids, PDE-4 inhibitors, anti-muscarinic agents, cromolyn sodium, H 1 receptor antagonists, 5-HT 1 agonists, NSAIDs, angiotensin-converting enzyme inhibitors, angiotensin II receptor agonists, β-blockers, β-agonists, leukotriene antagonists, diuretics, aldosterone antagonists, ionotropic agents, and natriuretic peptides.
5. A compound which has the formula
or a pharmaceutically acceptable salt thereof.
6. The pharmaceutical composition of claim 3 , wherein said additional therapeutic agents are selected from the group consisting of pain management agents, anti-anxiety agents, anti-migraine agents, and therapeutic agents suitable for treating heart conditions, psychotic disorders, and glaucoma.
7. The compound which has the formula
or a pharmaceutically acceptable salt thereof.